Robert Lehman

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

Patrick G. Morris, Carol Chen, Richard M. Steingart et al. · Clinical Cancer Research · 2011 · 141 citations · Full text

Medicine, Oncology, Pharmacology +15

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Clifford A. Hudis, Charles Swanton, Yelena Y. Janjigian et al. · Breast Cancer Research · 2013 · 105 citations · Full text

Medicine, Oncology, Pharmacology +17

Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

Patrick G. Morris, Neil M. Iyengar, Sujata Patil et al. · Cancer · 2013 · 20 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.

Hyo S. Han, Charles Swanton, Y. Y. Janjigian et al. · Journal of Clinical Oncology · 2011 · 15 citations

Medicine, Oncology, Pharmacology +16